. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Pharmacotherapy. 2015 Mar 10;35(4):361–369. doi: 10.1002/phar.1560

Table 2.

Summary of Midazolam and 1′-hydroxymidazolam Pharmacokinetics Before and After Roux-en-Y Gastric Bypass (mean ± SD)

	Baseline (n=9)	3 mo (n=9)	12 mo (n=9)
Midazolam
C_max, ng/ml	9.67 ± 6.72	16.09 ± 6.65^a	16.56 ± 7.55^a
T_max, hr	0.61 ± 0.22	0.28 ± 0.08^a	0.26 ± 0.08^a
Vd/F, L	763 ± 254	553 ± 219^a	506 ± 260^a
Cl/F, L/hr	91.9 ± 74.4	100.6 ± 58.6	100.1 ± 40.2
t_1/2, hr	8.0 ± 3.7	5.3 ± 3.7	4.5 ± 4.3
AUC_0–last, ng·hr/ml	20.8 ± 10.7	20.3 ± 10.8	18.3 ± 7.9
AUC_0–∞, ng·hr/ml	31.2 ± 15.7	26.8 ± 14.7	23.8 ± 11.2
1′-Hydroxymidazolam
C_max, ng/ml	3.19 ± 2.01	5.97 ± 2.11^a	5.75 ± 2.00^a
T_max, hr	0.69 ± 0.29	0.35 ± 0.10^a	0.31 ± 0.05^a
t_1/2, hr	3.3 ± 1.3	2.5 ± 1.2	2.1 ± 1.3
AUC_0–last, ng·hr/ml	6.5 ± 3.9	8.1 ± 3.4	7.1 ± 1.9
AUC_0–∞, ng·hr/ml	8.5 ± 4.2	9.8 ± 3.9	8.2 ± 2.0
1′OH MDZ:MDZ AUC ratio	0.35 ± 0.27	0.47 ± 0.28	0.40 ± 0.14

AUC = area under the concentration-time curve; Cl/F = oral clearance; C_max = peak plasma concentration; t_1/2 = serum half-life; T_max = time to peak plasma concentration; Vd/F = apparent volume of distribution.

p<0.05 compared with baseline.